TELIX Pharmaceuticals Ltd (TLX) - Total Assets
Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) holds total assets worth AU$1.19 Billion AUD (≈ $841.97 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TELIX Pharmaceuticals Ltd net assets for net asset value and shareholders' equity analysis.
TELIX Pharmaceuticals Ltd - Total Assets Trend (2000–2024)
This chart illustrates how TELIX Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data.
TELIX Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
TELIX Pharmaceuticals Ltd's total assets of AU$1.19 Billion consist of 60.6% current assets and 39.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 46.8% |
| Accounts Receivable | AU$158.99 Million | 10.5% |
| Inventory | AU$38.14 Million | 2.5% |
| Property, Plant & Equipment | AU$54.32 Million | 3.6% |
| Intangible Assets | AU$309.49 Million | 20.4% |
| Goodwill | AU$106.65 Million | 7.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how TELIX Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TELIX Pharmaceuticals Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TELIX Pharmaceuticals Ltd's current assets represent 60.6% of total assets in 2024, an increase from 32.5% in 2000.
- Cash Position: Cash and equivalents constituted 46.8% of total assets in 2024, up from 31.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 20.4% of total assets.
TELIX Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of TELIX Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
TELIX Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 0.99 | 4.32 |
| Quick Ratio | 1.22 | 0.87 | 4.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$99.43 Million | AU$-3.11 Million | AU$33.82 Million |
TELIX Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between TELIX Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.61 |
| Latest Market Cap to Assets Ratio | 2.16 |
| Asset Growth Rate (YoY) | 280.7% |
| Total Assets | AU$1.52 Billion |
| Market Capitalization | $3.27 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values TELIX Pharmaceuticals Ltd's assets at a significant premium (2.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: TELIX Pharmaceuticals Ltd's assets grew by 280.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TELIX Pharmaceuticals Ltd (2000–2024)
The table below shows the annual total assets of TELIX Pharmaceuticals Ltd from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$1.52 Billion ≈ $1.07 Billion |
+280.72% |
| 2023-12-31 | AU$398.30 Million ≈ $281.82 Million |
+55.98% |
| 2022-12-31 | AU$255.35 Million ≈ $180.68 Million |
+132.53% |
| 2021-12-31 | AU$109.81 Million ≈ $77.70 Million |
-30.42% |
| 2020-12-31 | AU$157.82 Million ≈ $111.67 Million |
+53.81% |
| 2019-12-31 | AU$102.61 Million ≈ $72.60 Million |
+33.76% |
| 2018-12-31 | AU$76.71 Million ≈ $54.28 Million |
+50.13% |
| 2017-12-31 | AU$51.09 Million ≈ $36.15 Million |
+443.90% |
| 2000-12-31 | AU$9.39 Million ≈ $6.65 Million |
-- |
About TELIX Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more